MiR-373 Inhibits the Epithelial-Mesenchymal Transition of Prostatic Cancer via Targeting Runt-Related Transcription Factor 2

1. Introduction

Prostatic cancer (PCa) is a prevalent form of malignancy based on its high associated levels of mortality and morbidity across the world. MicroRNAs (miRNAs) are significant in the advancement of prostatic cancer. The current study is aimed at exploring the potential roles of miR-373 in PCa. In turn, the study conducted a qRT-PCR test to determine the levels of mRNA. A western blot test was also executed in determining the protein level. The processes of transwell assay and wound healing were integrated in the detection of the potential for PCa cells to invade and migrate. The integration of dual luciferase reporter assay is critical in determining the levels of luciferase activity among prostatic cancer cells. Then, the results showed a net decrease of miR-373 within prostatic cancer cells and tissues. Upregulated miR-373 reduced the invasion and migration potential of PCa cells. Moreover, overexpressed miR-373 increased the levels of E-cadherin and FSP1 as epithelial cell markers. Similarly, the overregulation of miR-373 brought about the upregulation of mesenchymal markers (N-cadherin, Snail, and vimentin). The study predicted runt-related transcription factor 2 (RUNX2) to be a target of miR-373. The luciferase activity of PCa cells was decreased after the cotransfection with miR-373 mimics and RUNX2 3′ untranslated region (3′ UTR) wild type (WT). Moreover, RUNX2 became upregulated in PCa cells and tissues. The upregulation of miR-373 decreased the mRNA and protein level of RUNX2. However, overexpressed RUNX2 abated the roles of miR-373 in the intrusion and migration of PCa cells and in regulating the expression of epithelial cell markers and mesenchymal markers. In short, miR-373 may regulate the EMT of PCa cells via targeting RUNX2. The miR-373/RUNX2 axis provides a therapeutic target for PCa.
Besides, miRNAs degrade gene level through their potential to bind to the 3′ untranslated region (3′UTR) within the target genes [11]. Intensive bodies of evidence have reported that miRNAs participate in multiple biological processes, including proliferation, cell differentiation, invasion, apoptosis, and migration, and epithelial-mesenchymal transition [12, 13]. Moreover, the aberrant expressed miRNAs are significant in facilitating the progression and emergence of cancer, including PCa. For instance, miR-373 is downregulated in non-small cell lung cancer (NSCLC), while overexpressed miR-373 suppresses EMT of NSCLC cells [14]. Upregulated miR-373 promotes EMT of tongue squamous cell carcinoma. MiR-373 is decreased in human epithelial ovarian cancer (EOC), while its overexpression suppresses the invasion and EMT of EOC cells [15]. MiR-373 inhibits the invasion of progression of PCa [16]. However, the underlying mechanisms is still unclear.

Still, RUNX2 is firstly reported to participate in the skeletal embryogenesis. In recent years, its oncogenic properties have been attracting increasing attention. RUNX2 is involved in the initiation and progression of numerous cancers [17–19]. RUNX2 acts as an oncogene and regulates the apoptosis, migration, proliferation, invasion, and EMT of malignant cells via unchecked signaling pathways [18, 19]. In PCa, overexpressed RUNX2 is associated with high-grade prostatic intraepithelial neoplasia (HGPIN), cancerous lesions, and prostate tumorigenesis [20]. However, the possible roles of RUNX2 in EMT of PCa have not been elucidated.

In this study, transwell assay and wound healing were applied to examine the implications of overexpressed miR-373 on the processes of invasion and migration among PCa cells. The concept of luciferase assay has the potential of providing novel therapeutic target and was thus used in verifying whether RUNX2 was a target of miR-373. In summary, the study was based on the purpose of investigating the potential roles of miR-373 in the EMT of PCa and the underlying molecular mechanisms.

2. Methods

2.1. Clinical Samples. Tissue samples from the PCa as well as normal tissues in adjacent locations were selected from 30 patients diagnosed with PCa. Besides, the control population entailed patients that had benign prostatic hyperplasia (BPH) during August, 2017, to January, 2019, at The Affiliated Weihai Second Municipal Hospital of Qingdao University. The samples were immediately placed at a temperature of −80°C following the surgery. Besides, the participants have not received chemotherapy or radiotherapy prior to this study. The supervision of the research was conducted by the Institutional Review Board within the sponsoring institution. However, all participants were required to sign and provide informed consent.

2.2. Cell Culture. The researchers purchased their cell culture from ATCC and included normal prostate epithelia cell line alongside LNCaP, and DU145. Similarly, human PCa cell lines PC3 were also sourced from the cell culture in ATCC. Cells were incubated in a basal medium with 10% concentration of FBS and Penicillin-Streptomycin at 1%. Moreover, the temperature of the incubator was controlled at 37°C with 5% CO₂. The cells were subjected to a confluence of 80% through the process of being passaged.

2.3. Transfection. The transfection of PC3 cells was achieved using 50 nM of miR-373 mimics (Mimics) or miR-NC mimics (NC mimics) using Lipofectamine 2000 (Invitrogen, USA) for 48 h. pcDNA3.1 and pcDNA3.1-RUNX2 were synthesized and provided by GenePharma (Shanghai, China). The transfection of the cells was achieved using either pcDNA3.1-RUNX2 or pcDNA3.1 based on the manufacturer’s protocols that use lipofectamine 2000.

2.4. qRT-PCR. The choice of reagent for isolating total RNA from the localized cells and tissues was TRIzol. The collected RNA was then transcribed into cDNA with PrimeScript RT kit (Takara, Japan) based on the manufacturer’s instructions. The PCR was conducted using SYBR® Premix ExTaq™ II Kit (Takara, Japan) under the prescribed thermo cycling condition. Particularly, it was exposed to five minutes at 95°C, and 40 more cycles averaging 30 seconds at a temperature of 95°C. Finally, it was subjected to further cycles of 45 sec at 60°C. Then, a calculation of the expression level was made using 2−∆∆CT method. In turn, U6 was regularized to the prescribed levels of miRNA and GAPDH to mRNA.

2.5. Western Blot. Cells or tissues were lysed. Total protein was collected with RIPA buffer (Sigma-Aldrich, USA). Then, total protein was isolated with 12% SDS-PAGE. Afterwards, the protein was moved onto PVDF membranes, which was then blocked with milk that possessed nonfat attributes. The membranes would then be incubated over the night by relying on primary antibodies and being put in temperatures of 4°C in shade and then with secondary antibodies. Subsequently, the protein was visualized, and the relative protein level was calculated.

2.6. Wound Healing Assay. After 48 h transfection, cells became cultured with a 6-well plate (3×104 cells/well) overnight till the cells reached 80–90% confluency. Then, a pipette tip was applied to make a scratch. The cell movement was pictured and analyzed.

2.7. Transwell Assay. The cells were placed into a 24-well plate (2×103 cells/well) and then incubated in the upper chamber containing Matrigel and serum-free DMEM. Inherently, the bottom chamber was treated with 10% FBS. Within a day, the noninvasive cells were removed. Next, the invaded cells were corrected with 4% methanol while crystal violet was used for staining. Finally, the cells were captured before being calculated.
2.8. Dual Luciferase Reporter Assay. The online database across TargetScan 7.2 (https://www.targetscan.org/vert_72/) was utilized to forecast the target of miR-373. The 3’ untranslated region (3’UTR) sequences containing the potential target of miR-373 were synthesized and cloned into reporter gene plasmid vector pGL3 to build RUNX2 3’UTR wild type and RUNX2 3’UTR Mutant (MUT) plasmids. Then, the transfection of the cells was achieved using either miR-373 NC or the same variant with an accompanying Lipofectamine 2000 at 37°C with 5% CO₂. The determination of the cell luciferase activity was consistent with the Dual-Luciferase Reporter Assay System (Promega, USA).

2.9. Statistical Analysis. Data collected in the study was analyzed with SPSS22.0 software and represented through calculations of mean ± standard deviation (mean ± SD). The variances between the two groups were considered using Student’s t-test, while the variances in multigroups were evaluated with one-way ANOVA. The statistical significance was set at \( P < 0.05 \).

3. Results

3.1. MiR-373 Is Downregulated in PCa Tissues. qRT-PCR was executed to identify the manifestation of miR-373 in PCa tissues as well as the normal tissues adjacent to the malignant cells. As shown in Figure 1, the expression of miR-373 was downregulated in PCa tissues relative to the normal tissues in adjacent locations, thereby suggesting that miR-373 may be an antitumor miRNA in PCa.

3.2. MiR-373 Is Decreased in PCa Cells. In exploring the roles of miR-373 in PCa, we also detected the expression of miR-373 in PCa cells. The findings also portrayed a decrease in the volume of miR-373 in PCa cell lines, such as PC3, LNCaP, and DU145, compared with prostate epithelial cell line RWPE-1, which was more potent in PC3 (Figure 2(a)). Then, PC3 cells were used in the following experiment. Moreover, the manifestation of miR-373 in PCa cells was transfected with miR-373 mimics was upregulated in comparison with control populations, which suggested PC3 were successfully transfected (Figure 2(b)).

3.3. MiR-373 Inhibits the EMT of PCa Cells. The processes of transwell assay and wound healing were executed to test the implications of miR-373 on the invasion and migration of PCa cells. As shown in Figure 3(a), the scratch width of the miR-373 mimics transfected cells showed no significant difference. In turn, the healing rate was significantly decreased, suggesting that miR-373 inhibited the potential for PCa cells to migrate. Moreover, the ability of PCa cells to invade is significantly inhibited when transfected with miR-373 mimics, relative to the control group (Figure 3(b)). Meanwhile, overexpressed miR-373 downregulated N-cadherin, Snail, and vimentin and upregulated E-cadherin and FSP1, suggesting miR-373 played an inhibitory role in the EMT of PCa cells (Figure 3(c)).

3.4. MiR-373 Directly Targets RUNX2. The research predicted RUNX2 as a target of miR-373 (https://www.targetscan.org/vert_72/). The binding locations between miR-373 and RUNX2 are shown in Figure 4(a). The findings from the luciferase assay portrayed the fact that the luciferase activity of PCa cells was transfected along with miR-373 mimics and RUNX 3’UTR WT was considerably decreased compared with NC mimics group (Figure 4(b)). The protein rates of RUNX2 were upregulated in PCa cells and tissues (Figures 4(c) and 4(d)). However, the mRNA of RUNX2 was also downregulated following its transfection with miR-373 mimics, which was paralleled with the protein level (Figures 4(e) and 4(f)).

3.5. Overexpressed RUNX2 Alleviates Inhibition of EMT Induced by MiR-373 Mimics in PCa. Rescue assay was performed to examine the roles of RUNX2 in the EMT of PCa cells. As shown in Figures 5(a) and 5(b), upregulated miR-373 reduced the potential for invasion and migration among PCa cells when compared with NC mimics, which was reversed by the overexpression of RUNX2. Moreover, the regulatory role of miR-373 in the depiction of EMT-related genes (such as N-cadherin, Snail, vimentin, E-cadherin and FSP1) was alleviated by RUNX2, where upregulated RUNX2 alleviated the effects of miR-373 on the EMT of PCa cells (Figure 5(c)).

4. Discussion

Augmenting bodies of evidence have revealed miRNAs have a significant role in the initiation and sustenance of PCa [16, 21, 22]. The aberrant expressed miRNAs suppress the identified tumors in PCa. For instance, downregulated miR-129-3p is associated with TNM staging, differentiation of PCA tumor, and lymph node metastasis, while its overexpression inhibited the spread and invasion of PCa cells [23]. miR-601 functions as an oncogene in PCa. As such, it alleviates the potential for migration, invasion, and progression of PCa cells [24]. Meanwhile, Qiu et al. demonstrated that the downregulation of miR-373-3p induces the
Figure 2: MiR-373 is decreased in PCa cells. (a) The manifestation of miR-373 in PCa cells. (b) The transfection efficacy of PCa cells determined by qRT-PCR. **P < 0.01 vs. RWPE-1 cells or even control populations.

Figure 3: Continued.
**Figure 3:** MiR-373 inhibits the EMT of PCa cells. (a) The potential for migration in PCa cells determined by wound healing assay. (b) The potential for invasion in PCa cells examined through transwell assay. (c) The protein level of N-cadherin, Snail, and vimentin and E-cadherin and FSP1 measured by western blot. **P < 0.01 vs. control group.

RUNX2 3' UTR WT 5' ...UGUGUUGUUUCAGCAGCACUUA... 3'  
hsa-miR-373-3p 3' ...UGUGGGGUUUUAGCUUCGUGAAG 5'  
RUNX2 3' UTR MUT 3' ...UGUGUUGUUUCAGCUUCGUGAAA... 3'  

**Figure 4:** Continued.
Figure 4: MiR-373 directly targets RUNX2. (a) The binding sites of miR-373 on RUNX2. (b) The activity of luciferase within PCa cells was established through Dual luciferase reporter assay. (c) The levels of protein in RUNX2 of PCa tissues determined by western blot. (d) The levels of protein of RUNX2 in PCa cells were identified by western blot. (e) The level of mRNA of RUNX2 in PCa cells calculated with qRT-PCR. (f) The level of protein in RUNX2 measured by western blot. **P < 0.01 vs. normal tissues, RWPE-1 cells, or control group.

Figure 5: Continued.
metastasis of PCa, and the silence of testicular nuclear receptor 4 (TR4) or the upregulation of miR-373-3p may be a likely target for PCa [25]. (V here was a reduction of miR-373 in PCa cells and tissues, thereby suggesting that miR-373 serves as an antitumor gene in PCa. (V hese results are consistent with Qiu et al.’s study [25]. However, the possible mechanism that miR-373 regulated the progression of PCa is still unclear.

Epithelial-mesenchymal transition (EMT) is a complicated progress involved in the metastasis, stemness, and drug resistance of PCa [26]. EMT progresses with the loss of epithelial functions and acquisition of mesenchymal features [27]. This degradation from cuboidal to spindle-shaped in cell phenotype is accompanied with the downregulation of epithelial cell markers (E-cadherin, occludins, and FSP1). Similarly, mesenchymal markers such as vimentin and N-cadherin have been upregulated and further activating the master regulator of EMT, such as Snail and Twist [28, 29]. (V hence, to explore the expected molecular mechanisms involved in the EMT of PCa cells to inhibit the metastasis is of vital importance. Still, miRNAs contribute to the initiation and sustenance of cancers via regulating multiple biological processes including EMT [12, 13]. In this study, upregulated miR-373 reduced the potential for invasion and migration among PCa cells. Moreover, its overexpression decreased the expression of mesenchymal markers (vimentin and N-cadherin) and the master regulator of EMT (Snail) and enhanced the manifestation of epithelial cell markers (E-cadherin and FSP1), which suggested the upregulation of miR-373 repressed the loss of epithelial functions and acquisition of mesenchymal features, and therefore inhibited the progression of EMT of PCa cells. However, the underlying mechanisms is still unknown.

miRNAs regulate biological functions through provision of bonds to the 3'UTR of the identified genes [11]. Runx-related transcription factor 2 (RUNX2) was predicted and proved to be a target of miR-373. Increasing studies have reported the upregulation of RUNX2 derived from epithelial tissues induces the progression of mutitype cancers [17–19]. RUNX2, as a lineage specific transcription factor, collectively participates in EMT and promotes the maturation of mesenchymal markers via interacting with specific pathways related to these pathophysiological processes [30, 31]. In PCa, the abnormal upregulation of RUNX2 contributes to EMT of PCa cells and PCa to bone metastasis [32]. In the current study, RUNX3 was upregulated in PCa cells and tissues. Interestingly, overexpressed RUNX2 reversed the alleviation of PCa invasion and migration and abrogated the upregulation of epithelial markers and the downregulation of mesenchymal markers in induced by miR-373. The findings suggested the regulatory role of miR-373 in PCa EMT was alleviated by RUNX2. (V hese findings suggested the regulatory role of miR-373 in PCa EMT was alleviated by RUNX2. Therefore, miR-373 may inhibit the EMT of PCa cells via targeting RUNX2.

In conclusion, miR-373 was downregulated in PCa cells and tissues. Overexpressed miR-373 inhibited the transition from epithelial to mesenchymal state for PCa through targeting PCa. In turn, the inhibition of this transition provides a significant strategy in the treatment of prostate cancer (PCa).

However, the present study has some limitations. Firstly, more patients are needed to make the results more convincing. Secondly, a miRNA may have more than one target, which may be targeted by various miRNAs. Therefore, the underlying mechanisms that miR-373 regulates the EMT of PCa need further research. Furthermore, this study needs to be combined with other hospitals for multicenter research in the future to promote the basic treatment of liver cancer.

Data Availability
The simulation experiment data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare no conflicts of interest.

Authors’ Contributions
Jianyi Pang drafted the paper and cooperated with Limei Dai to conduct the experiment, with Qinglei Zhang to collect the
data, and with Chen Zhang to interpret the data. Qinglei Zhang designed this work.

Acknowledgments
This paper was supported by the Research Support Fund for Teachers of Jining Medical University (No. JYFC2018FKJ169).

References
[1] M. C. S. Wong, W. B. Goggins, H. H. X. Wang et al., “Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries,” European Urology, vol. 70, no. 5, pp. 862–874, 2016.
[2] J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015.
[3] C. Liu, T. Liu, N. Zhang et al., “68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 45, no. 11, pp. 1852–1861, 2018.
[4] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015.
[5] C. K. Zhou, D. P. Check, J. Lortet-Tieulent et al., “Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group,” International Journal of Cancer, vol. 138, no. 6, pp. 1388–1400, 2016.
[6] B. Ha Chung, S. Horie, and E. Chiong, “The incidence, mortality, and risk factors of prostate cancer in Asian men,” Prostate International, vol. 7, no. 1, pp. 1–8, 2019.
[7] K. P. Weinfurt, Y. Li, L. D. Castel et al., “The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer,” Annals of Oncology, vol. 16, no. 4, pp. 579–584, 2005.
[8] S. Lamouille, J. Xu, and R. Derynck, “Molecular mechanisms of epithelial-mesenchymal transition,” Nature Reviews Molecular Cell Biology, vol. 15, no. 3, pp. 178–196, 2014.
[9] A. Dongre and R. A. Weinberg, “New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer,” Nature Reviews Molecular Cell Biology, vol. 20, no. 2, pp. 69–84, 2019.
[10] N.-B. Hao, Y.-F. He, X.-Q. Li, K. Wang, and R.-L. Wang, “The role of miRNA and lncRNA in gastric cancer,” Oncotarget, vol. 8, no. 46, pp. 81572–81582, 2017.
[11] D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009.
[12] W. Chang, M. Liu, J. Xu et al., “MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3,” Tumor Biology, vol. 37, no. 11, pp. 14813–14824, 2016.
[13] F. Huang, J. Tang, X. Zhuang et al., “MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha,” PLoS One, vol. 9, no. 2, Article ID e87897, 2014.
[14] L. Wang, J. Qu, L. Zhou, F. Liao, and J. Wang, “MicroRNA-373 inhibits cell proliferation and invasion via targeting BRF2 in human non-small cell lung cancer A549 cell line,” Cancer Research and Treatment, vol. 50, no. 3, pp. 936–949, 2018.
[15] Y. Zhang, F.-J. Zhao, L.-L. Chen et al., “MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer,” Oncotarget, vol. 5, no. 23, pp. 12291–12303, 2014.
[16] K. Yang, A. M. Handorean, and K. A. Iczkowski, “MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro,” International Journal of Clinical and Experimental Pathology, vol. 2, no. 4, pp. 361–369, 2009.
[17] J. Pratap, J. B. Lian, A. Javed et al., “Regulatory roles of runx2 in metastatic tumor and cancer cell interactions with bone,” Cancer and Metastasis Reviews, vol. 25, no. 4, pp. 589–600, 2006.
[18] J. Akech, J. J. Wixted, K. Bedard et al., “Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions,” Oncogene, vol. 29, no. 6, pp. 811–821, 2010.
[19] T. Ozaki, M. Yu, and D. Yin, “Impact of runx2 on drug-resistant human pancreatic cancer cells with p53 mutations,” BMC Cancer, vol. 18, no. 1, p. 309, 2018.
[20] Y. Yang, Y. Bai, Y. He et al., “PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer,” Clinical Cancer Research, vol. 24, no. 4, pp. 834–846, 2018.
[21] L. Xia, Q. Han, C. Chi et al., “Transcriptional regulation of PKRAR2B by miR-200b-3p/200c-3p and XBPI in human prostate cancer,” Biomedicine & Pharmacotherapy, vol. 124, Article ID 109863, 2020.
[22] Z. Xing, S. Li, Z. Liu, C. Zhang, and Z. Bai, “CTCF-induced upregulation of HOXA11-AS facilitates cell proliferation and migration by targeting miR-518b/ACTN4 axis in prostate cancer,” The Prostate, vol. 80, no. 5, pp. 388–398, 2020.
[23] Y. Jia, Y. Gao, and J. Dou, “Effects of miR-129-3p on biological functions of prostate cancer cells through targeted regulation of smad3,” Oncology Letters, vol. 19, no. 2, pp. 1195–1202, 2020.
[24] H. Du, X. Wang, R. Dong, D. Hu, and Y. Xiong, “MIR-601 inhibits proliferation, migration and invasion of prostate cancer stem cells by targeting KRT5 to inactivate the wnt signaling pathway,” International Journal of Clinical and Experimental Pathology, vol. 12, no. 12, pp. 4361–4379, 2019.
[25] X. Qiu, J. Zhu, Y. Sun et al., “TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFβ2/Rp-Smad3 signals,” Oncotarget, vol. 6, no. 17, pp. 15397–15409, 2015.
[26] Y. Du, X.-H. Liu, H.-C. Zhu, L. Wang, J.-Z. Ning, and C.-C. Xiao, “MIR-543 promotes proliferation and epithelial-mesenchymal transition in prostate cancer via targeting RKIP,” Cellular Physiology and Biochemistry, vol. 41, no. 3, pp. 1135–1146, 2017.
[27] C. Zhiping, T. Shijun, W. Linhui, W. Yapei, Q. Lianxi, and D. Qiang, “MIR-181a promotes epithelial to mesenchymal transition of prostate cancer cells by targeting TGFβ2,” European Review for Medical and Pharmacological Sciences, vol. 21, no. 21, pp. 4835–4843, 2017.
[28] Y. Guan, H. Shi, and T. Xiao, “NUAK1 knockdown suppresses prostate cancer cell epithelial-mesenchymal transition, migration, and invasion through microRNA-30b-5p,” International Journal of Clinical and Experimental Pathology, vol. 11, no. 12, pp. 5694–5704, 2018.
[29] S. Basu, A. Chaudhary, P. Chowdhury et al., “Evaluating the role of hsa-miR-200c in reversing the epithelial to mesenchymal transition in prostate cancer,” Gene, vol. 730, Article ID 144264, 2020.
[30] A. M. Herreño, A. C. Ramírez, and V. P. Chaparro, "Role of RUNX2 transcription factor in epithelial mesenchymal transition in non-small cell lung cancer: epigenetic control of the RUNX2 P1 promoter," *Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine*, vol. 41, no. 5, 2019.

[31] X. Bai, L. Meng, H. Sun, Z. Li, X. Zhang, and S. Hua, "MicroRNA-196b inhibits cell growth and metastasis of lung cancer cells by targeting Runx2," *Cellular Physiology and Biochemistry*, vol. 43, no. 2, pp. 757–767, 2017.

[32] M. Colden, A. A. Dar, S. Saini et al., "MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2," *Cell Death & Disease*, vol. 8, no. 1, Article ID e2572, 2017.